Yu Chen,nian Liu,shufan Feng,Wenhui Xu,Chun Mao,Mimi Wan
The combination of cancer vaccines and chemotherapy represents a promising therapeutic strategy for tumor treatment. However, the commonly used intravenous injection method often results in limited therapeutic efficacy. To address this challenge, we develop a therapeutic nanomotor cancer vaccine capable of activating immune responses and employ microneedle technology to achieve efficient co-delivery of the nanomotor cancer vaccine and the chemotherapeutic drug doxorubicin (DOX). The nanomotor cancer vaccine is prepared using the desolvation method, with its primary components including the cancer vaccine formed by self-assembly of bovine serum albumin (BSA) and the antigen ovalbumin (OVA), as well as L-arginine (LA) loaded via physical adsorption. These components are co-encapsulated into hyaluronic acid-based microneedles. Upon insertion into the skin, the hyaluronic acid matrix rapidly dissolves, releasing the nanomotor cancer vaccine (OVA/BSA-LA). The LA component enables the nanomotor to specifically target tumor tissues by binding to the highly expressed inducible nitric oxide synthase (iNOS), achieving chemotactic tumor targeting. The nitric oxide (NO) generated during this process induces immunogenic cell death in tumor cells, while the antigen OVA promotes immune cell maturation, activates T cell differentiation, and triggers antitumor immune responses. When combined with DOX, the therapeutic efficacy is further enhanced. In vitro and in vivo experiments demonstrate that the microneedle-based nanomotor cancer vaccine, in combination with chemotherapy, exhibits good efficacy in treating melanoma, offering a promising strategy for melanoma therapy.
Mengxin Xu,Ying Liu,Huimin Chen,Weilun Hu,Yingying Li,Yuxin Zhang,Qingqing Wang,Tao Ma
s Vaccines play a crucial role in managing pandemic diseases like SARS and emerging coronaviruses. Efficient and quick detection methods for antigen-specific antibodies could significantly aid in designing vaccines intelligently. Presently, the detection of these antibodies typically involves the collection of blood and subsequent enzyme-linked immunosorbent assay, lateral flow immunoassay, and similar assay techniques. However, blood collection causes patient discomfort and pain, requiring professional handling and often resulting in poor patient compliance. This work is based on the establishment of a rapid vaccine antibody detection technique based on microneedle technology, in which microneedles modified with bio-recognition elements (such as antigens) penetrate the stratum corneum to extract interstitial fluid through capillary action and selectively capture protein biomarkers (such as antibodies) in the ISF in a concentration-dependent manner. The protein biomarkers attached to the microneedles are subsequently identified using an in vitro fluorescence immunoassay. This study merges the specificity inherent in antigen-antibody binding with the porous characteristics of microneedles to swiftly capture and detect antibodies within the skin's interstitial fluid. Compared to conventional testing methods, microneedle technology doesn't necessitate blood collection, rendering the technique non-invasive, minimally uncomfortable, and highly efficient. Moreover, it enables rapid antibody detection, offering a promising and straightforward approach to the efficient detection of various antibodies.
危险品化学品经营许可证（带存储）